[{"id":"d706a100-20c3-4942-98f1-dac486c56909","acronym":"ORIENTA","url":"https://clinicaltrials.gov/study/NCT06102824","created_at":"2023-10-26T15:14:20.313Z","updated_at":"2024-07-02T16:35:23.595Z","phase":"Phase 2","brief_title":"Organoid-based Functional Precision Therapy for Advanced Breast Cancer","source_id_and_acronym":"NCT06102824 - ORIENTA","lead_sponsor":"Guangdong Provincial People's Hospital","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HR positive • HER-2 negative • ER positive + PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • ER positive + PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • albumin-bound paclitaxel • cyclophosphamide • Halaven (eribulin mesylate) • pegylated liposomal doxorubicin • vinorelbine tartrate • Trodelvy (sacituzumab govitecan-hziy) • Ixempra (ixabepilone) • Lipusu (liposomal paclitaxel) • utidelone IV (UTD1)"],"overall_status":"Recruiting","enrollment":" Enrollment 252","initiation":"Initiation: 01/20/2024","start_date":" 01/20/2024","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2024-01-12"}]